{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:54:07Z","timestamp":1788976447014,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Traditional Chinese Scientific and Technological Projects for Medicine and Health of Zhejiang Province","award":["2025ZL004"],"award-info":[{"award-number":["2025ZL004"]}]},{"name":"Zhejiang Medical Association Special Fund Program for Clinical Medicine","award":["2024ZYC-A259"],"award-info":[{"award-number":["2024ZYC-A259"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>While sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are known to lower serum uric acid (SUA) in heart failure with reduced ejection fraction (HFrEF) or diabetes, their urate-lowering effect in heart failure with preserved ejection fraction (HFpEF) remains unclear. This study aimed to evaluate this effect in HFpEF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HFpEF patients newly treated with SGLT-2i were retrospectively included. Changes in SUA level and gout events were analyzed during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We selected 734 patients according to propensity score matching, with the median age of 75.0(66.0\u201385.0) years. 31.9% were combined with chronic kidney disease(CKD) and the mean SUA was 6.4\u2009\u00b1\u20091.9\u00a0mg\/dl. At 3 to 6-month follow-up, SGLT-2i treatment (79.6% dapagliflozin ) was associated with greater reduction of SUA (-0.91\u2009\u00b1\u20091.63\u00a0mg\/dl vs. -0.10\u2009\u00b1\u20091.54\u00a0mg\/dl;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and fasting glucose (-0.49(-1.59 to 0.37) vs. 0(-0.83 to 0.39) mmol\/l,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). 16 cases in SGLT-2i group had gout events and 23 cases in control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.25). No significant difference was analyzed in estimated glomerular filtration rate (eGFR) change between groups. The control rate of SUA (&lt;\u20096\u00a0mg\/dl) was 72.2% and 51.2% respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Multiple regression analysis suggested that changes of SUA were closely associated with gender, basal SUA level, eGFR and eGFR changes. Subgroup analysis showed that SGLT-2i could reduce SUA regardless of whether combined with diabetes or CKD, and the urate-lowering effect was more pronounced in those with underlying hyperuricemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT-2i (primarily dapagliflozin) could significantly reduce SUA level in HFpEF patients without increasing the risk of gout attack nor injuring renal function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-05627-w","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:45:41Z","timestamp":1771062341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of sodium-glucose cotransporter-2 inhibitors on uric acid in patients with heart failure and preserved ejection fraction: a retrospective analysis in real word"],"prefix":"10.1186","volume":"26","author":[{"given":"Fangchao","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenkai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"19","key":"5627_CR1","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","volume":"375","author":"MM Redfield","year":"2016","unstructured":"Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016;375(19):1868\u201377. https:\/\/doi.org\/10.1056\/NEJMcp1511175.","journal-title":"N Engl J Med"},{"issue":"10","key":"5627_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction[J]. Nat Rev Cardiol. 2017;14(10):591\u2013602. https:\/\/doi.org\/10.1038\/nrcardio.2017.65.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"5627_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","volume":"3","author":"G Savarese","year":"2017","unstructured":"Savarese G, Lund LH. Global public health burden of heart failure[J]. Card Fail Rev. 2017;3(1):7\u201311. https:\/\/doi.org\/10.15420\/cfr.2016:25:2.","journal-title":"Card Fail Rev"},{"issue":"3","key":"5627_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ehf2.12418","volume":"6","author":"T Shiga","year":"2019","unstructured":"Shiga T, Suzuki A, Haruta S, et al. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan[J]. ESC Heart Fail. 2019;6(3):475\u201386. https:\/\/doi.org\/10.1002\/ehf2.12418.","journal-title":"ESC Heart Fail"},{"key":"5627_CR5","doi-asserted-by":"publisher","unstructured":"Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;23;359(17):1811\u20131821. https:\/\/doi.org\/10.1056\/NEJMra0800885.","DOI":"10.1056\/NEJMra0800885"},{"issue":"2","key":"5627_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jjcc.2013.03.009","volume":"62","author":"S Hamaguchi","year":"2013","unstructured":"Hamaguchi S, Kinugawa S, Miyuki Tsuchihashi-Makaya M, et al. Characteristics, management and outcomes for patients during hospitalization due to worsening heart failure-A report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD) [J]. J Cardiol. 2013;62(2):95\u2013101. https:\/\/doi.org\/10.1016\/j.jjcc.2013.03.009.","journal-title":"J Cardiol"},{"issue":"7","key":"5627_CR7","doi-asserted-by":"publisher","first-page":"H1123","DOI":"10.1152\/ajpheart.00533.2015","volume":"309","author":"T Shimizu","year":"2015","unstructured":"Shimizu T, Yoshihisa A, Kanno Y, et al. Relationship of hyperuricemia with mortality in heart failure patients with preserved ejection fraction [J]. Am J Physiol Heart Circ Physiol. 2015;309(7):H1123\u20131129. https:\/\/doi.org\/10.1152\/ajpheart.00533.2015.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"5627_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","volume":"16","author":"H Huang","year":"2014","unstructured":"Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis [J]. Eur J Heart Fail. 2014;16(1):15\u201324. https:\/\/doi.org\/10.1093\/eurjhf\/hft132.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"5627_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40256-020-00400-6","volume":"20","author":"MT Mouradjian","year":"2020","unstructured":"Mouradjian MT, Plazak ME, Gale SE, et al. Pharmacologic management of gout in patients with cardiovascular disease and heart failure [J]. Am J Cardiovasc Drugs. 2020;20(5):431\u201345. https:\/\/doi.org\/10.1007\/s40256-020-00400-6.","journal-title":"Am J Cardiovasc Drugs"},{"key":"5627_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.metabol.2018.02.007","volume":"83","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Targher G, Temporelli PL, et al. GISSI-HF Investigators. Prognostic impact of elevated serum uric acid levels on Long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per Lo studio Della Sopravvivenza Nella insufficienza Cardiaca-Heart Failure) trial [J]. Metabolism. 2018;83:205\u201315. https:\/\/doi.org\/10.1016\/j.metabol.2018.02.007.","journal-title":"Metabolism"},{"issue":"17","key":"5627_CR11","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"3","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines [J]. J Am Coll Cardiol. 2022;3(17):e263\u2013421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"5627_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41574-020-00453-2","volume":"17","author":"K Khunti","year":"2021","unstructured":"Khunti K. SGLT-2 inhibitors in people with and without T2DM [J]. Nat Rev Endocrinol. 2021;17(2):75\u20136. https:\/\/doi.org\/10.1038\/s41574-020-00453-2.","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"5627_CR13","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO) [J]. Diabetes Care. 2022;45(12):3075\u201390. https:\/\/doi.org\/10.2337\/dci22-0027.","journal-title":"Diabetes Care"},{"issue":"12","key":"5627_CR14","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD) [J]. Diabetes Care. 2018;41(12):2669\u2013701. https:\/\/doi.org\/10.2337\/dci18-0033.","journal-title":"Diabetes Care"},{"issue":"6","key":"5627_CR15","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ejhf.2433","volume":"24","author":"K McDowell","year":"2022","unstructured":"McDowell K, Welsh P, Docherty KF, et al. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF [J]. Eur J Heart Fail. 2022;24(6):1066\u201376. https:\/\/doi.org\/10.1002\/ejhf.2433.","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"5627_CR16","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","volume":"43","author":"W Doehner","year":"2022","unstructured":"Doehner W, Anker SD, Butler J, et al. Uric acid and sodium-glucose cotransporter-2 Inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial [J]. Eur Heart J. 2022;43(36):3435\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac320.","journal-title":"Eur Heart J"},{"key":"5627_CR17","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.2147\/TCRM.S186347","volume":"14","author":"Z Hao","year":"2018","unstructured":"Hao Z, Huang X, Shao H, Tian F. Effects of Dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial [J]. Ther Clin Risk Manag. 2018;14:2407\u201313. https:\/\/doi.org\/10.2147\/TCRM.S186347.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"5627_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/dom.14559","volume":"24","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Inzucchi SE, Mattheus M, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial [J]. Diabetes Obes Metab. 2022;24(1):135\u201341. https:\/\/doi.org\/10.1111\/dom.14559.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"5627_CR19","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.amjcard.2017.06.057","volume":"120","author":"A Palazzuoli","year":"2017","unstructured":"Palazzuoli A, Ruocco G, De Vivo O, et al. Prevalence of hyperuricemia in patients with acute heart failure with either reduced or preserved ejection fraction [J]. Am J Cardiol. 2017;120(7):1146\u201350. https:\/\/doi.org\/10.1016\/j.amjcard.2017.06.057.","journal-title":"Am J Cardiol"},{"issue":"11","key":"5627_CR20","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3760\/cma.j.issn.0253-3758.2019.11.004","volume":"47","author":"H Wang","year":"2019","unstructured":"Wang H, Li YY, Chai K, et al. Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47(11):865\u201374. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3758.2019.11.004. Chinese.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"7","key":"5627_CR21","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.hrthm.2014.04.003","volume":"11","author":"L Tamariz","year":"2014","unstructured":"Tamariz L, Hernandez F, Bush A, et al. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis [J]. Heart Rhythm. 2014;11(7):1102\u20138. https:\/\/doi.org\/10.1016\/j.hrthm.2014.04.003.","journal-title":"Heart Rhythm"},{"issue":"1","key":"5627_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13075-022-02812-y","volume":"24","author":"X Tian","year":"2022","unstructured":"Tian X, Zuo Y, Chen S, et al. High serum uric acid trajectories are associated with risk of myocardial infarction and all-cause mortality in general Chinese population [J]. Arthritis Res Ther. 2022;24(1):149. https:\/\/doi.org\/10.1186\/s13075-022-02812-y.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"5627_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.amjcard.2018.11.027","volume":"123","author":"C Zhang","year":"2019","unstructured":"Zhang C, Jiang L, Xu L, et al. Implications of hyperuricemia in severe coronary artery disease [J]. Am J Cardiol. 2019;123(4):558\u201364. https:\/\/doi.org\/10.1016\/j.amjcard.2018.11.027.","journal-title":"Am J Cardiol"},{"issue":"4","key":"5627_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s1388-9842(02)00086-7","volume":"4","author":"LE Spieker","year":"2002","unstructured":"Spieker LE, Ruschitzka FT, L\u00fcscher TF, et al. The management of hyperuricemia and gout in patients with heart failure [J]. Eur J Heart Fail. 2002;4(4):403\u201310. https:\/\/doi.org\/10.1016\/s1388-9842(02)00086-7.","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"5627_CR25","doi-asserted-by":"publisher","first-page":"e026301","DOI":"10.1161\/JAHA.122.026301","volume":"11","author":"M Nishino","year":"2022","unstructured":"Nishino M, Egami Y, Kawanami S, et al. Lowering uric acid May improve prognosis in patients with hyperuricemia and heart failure with preserved ejection fraction [J]. J Am Heart Assoc. 2022;11(19):e026301. https:\/\/doi.org\/10.1161\/JAHA.122.026301.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"5627_CR26","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American college of rheumatology guideline for the management of gout [J]. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360. https:\/\/doi.org\/10.1002\/acr.24180.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"5627_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/HJH.0000000000002589","volume":"39","author":"ML Muiesan","year":"2021","unstructured":"Muiesan ML, Salvetti M, Virdis A, from the Working Group on Uric Acid, et al. Cardiovascular risk of the Italian society of Hypertension. Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the uric acid right for heart health study. J Hypertens. 2021;39(1):62\u20139. https:\/\/doi.org\/10.1097\/HJH.0000000000002589.","journal-title":"J Hypertens"},{"issue":"20","key":"5627_CR28","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","volume":"131","author":"MM Givertz","year":"2015","unstructured":"Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of Xanthine oxidase Inhibition in hyperuricemic heart failure patients: the Xanthine oxidase Inhibition for hyperuricemic heart failure patients (EXACT-HF) study [J]. Circulation. 2015;131(20):1763\u201371. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.014536.","journal-title":"Circulation"},{"issue":"1","key":"5627_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","volume":"17","author":"A Whelton","year":"2011","unstructured":"Whelton A, Macdonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat[J]. J Clin Rheumatol. 2011;17(1):7\u201313. https:\/\/doi.org\/10.1097\/RHU.0b013e318204aab4.","journal-title":"J Clin Rheumatol"},{"issue":"23","key":"5627_CR30","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"8","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout [J]. N Engl J Med. 2005;8(23):2450\u201361. https:\/\/doi.org\/10.1056\/NEJMoa050373.","journal-title":"N Engl J Med"},{"key":"5627_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1475-2840-12-159","volume":"12","author":"Y Nishida","year":"2013","unstructured":"Nishida Y, Takahashi Y, Susa N, et al. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study [J]. Cardiovasc Diabetol. 2013;12:159. https:\/\/doi.org\/10.1186\/1475-2840-12-159.","journal-title":"Cardiovasc Diabetol"},{"key":"5627_CR32","doi-asserted-by":"publisher","unstructured":"Selvaraj S, Claggett BL, Pfeffer MA et al. Serum uric acid, influence of sacubitril-valsartan and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGONHF. Eur J Heart Fail. 2020;22(11):2093\u2013101. https:\/\/doi.org\/10.1002\/ejhf.1984.","DOI":"10.1002\/ejhf.1984"},{"issue":"4","key":"5627_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1053\/j.ajkd.2003.12.023","volume":"43","author":"VG Athyros","year":"2004","unstructured":"Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of Statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary- heart- disease evaluation (GREACE)study [J]. Am J Kidney Dis. 2004;43(4):589\u201399. https:\/\/doi.org\/10.1053\/j.ajkd.2003.12.023.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"5627_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/cpt197925133","volume":"25","author":"G Schrijver","year":"1979","unstructured":"Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension [J]. Clin Pharmacol Ther. 1979;25(1):33\u201342. https:\/\/doi.org\/10.1002\/cpt197925133.","journal-title":"Clin Pharmacol Ther"},{"issue":"15","key":"5627_CR35","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure [J]. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"21","key":"5627_CR36","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction [J]. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"5627_CR37","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/dom.13101","volume":"20","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT-2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials [J]. Diabetes Obes Metab. 2018;20:458\u201362. https:\/\/doi.org\/10.1111\/dom.13101.","journal-title":"Diabetes Obes Metab"},{"issue":"36","key":"5627_CR38","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [J]. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"9","key":"5627_CR39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41584-022-00804-5","volume":"18","author":"HK Choi","year":"2022","unstructured":"Choi HK, Zhang Y, Dalbeth N. When underlying biology threatens the randomization principle-initial gout flares of urate-lowering therapy[J]. Nat Rev Rheumatol. 2022;18(9):543\u20139. https:\/\/doi.org\/10.1038\/s41584-022-00804-5.","journal-title":"Nat Rev Rheumatol"},{"key":"5627_CR40","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/S2665-9913(19)30078-5","volume":"1","author":"J Li","year":"2019","unstructured":"Li J, Badve VS, Zhou Z, et al. The effects of Canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program[J]. Lancet Rheumatol 2019. 2019;1:e220\u20138. https:\/\/doi.org\/10.1016\/S2665-9913(19)30078-5.","journal-title":"Lancet Rheumatol 2019"},{"issue":"1","key":"5627_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/14397595.2020.1784556","volume":"31","author":"R Koto","year":"2021","unstructured":"Koto R, Nakajima A, Horiuchi H, et al. Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data [J]. Mod Rheumatol. 2021;31(1):261\u20139. https:\/\/doi.org\/10.1080\/14397595.2020.1784556.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"5627_CR42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","volume":"65","author":"M Goicoechea","year":"2015","unstructured":"Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: Long-term follow-up of a randomized clinical trial [J]. Am J Kidney Dis. 2015;65(4):543\u20139. https:\/\/doi.org\/10.1053\/j.ajkd.2014.11.016.","journal-title":"Am J Kidney Dis"},{"issue":"26","key":"5627_CR43","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa","volume":"382","author":"SV Badve","year":"2020","unstructured":"Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease [J]. N Engl J Med N. 2020;382(26):2504\u201313. https:\/\/doi.org\/10.1056\/NEJMoa.","journal-title":"N Engl J Med N"},{"issue":"24","key":"5627_CR44","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy [J]. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa.","journal-title":"N Engl J Med"},{"issue":"15","key":"5627_CR45","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease [J]. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa.","journal-title":"N Engl J Med"},{"issue":"1","key":"5627_CR46","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1038\/s41598-023-32072-y","volume":"13","author":"Y Iwata","year":"2023","unstructured":"Iwata Y, Notsu S, Kawamura Y, et al. The effect of Dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD [J]. Sci Rep. 2023;13(1):4849. https:\/\/doi.org\/10.1038\/s41598-023-32072-y.","journal-title":"Sci Rep"},{"key":"5627_CR47","doi-asserted-by":"publisher","first-page":"e926086","DOI":"10.12659\/MSM.926086","volume":"26","author":"N Ohashi","year":"2020","unstructured":"Ohashi N, Aoki T, Matsuyama T, et al. Sodium\u2013Glucose cotransporter-2 inhibitor immediately decreases serum uric acid levels in type 2 diabetic patients [J]. Med Sci Monit. 2020;26:e926086. https:\/\/doi.org\/10.12659\/MSM.926086.","journal-title":"Med Sci Monit"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05627-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05627-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05627-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:16:36Z","timestamp":1781633796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05627-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5627"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05627-w","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was consented by the Committee of Clinical Investigation of Zhejiang Hospital (Approval No.2024\u2013130\u00a0K) and conducted with the guidelines of the Declaration of Helsinki.The requirement for informed consent was waived by the ethics committee due to the retrospective and anonymized nature of the study (in accordance with Article 32 of the Declaration of Helsinki, the ICMJE Recommendations). All data handling adhered to China\u2019s Personal Information Protection Law and institutional privacy policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}